Emily Kobayashi (Gavi) outlined the transition to the Gavi 6.0 strategy during the 2025 CHIC Symposium. The intervention detailed the consolidation of multiple funding streams into a single holistic grant model and a unified cash envelope to enhance transparency and country sovereignty. Key policy shifts include the introduction of country vaccine budgets with financing ceilings […]
Topic: Sponsor Investments
Mises à jour sur l’élimination du cancer du col de l’utérus et le paysage de la vaccination contre le HPV: séance de questions-réponses
Emily Kobayashi (Responsable du programme PVH, Gavi) et des responsables du PEV (Guinée, Malawi, Cameroun, RDC) ont discuté de la mise en œuvre du modèle Gavi 6.0 lors du Symposium CHIC 2025. La session a précisé que la nouvelle subvention unifiée intègre les ressources de Gavi aux budgets nationaux et aux financements partenaires (ex. Banque […]
HPV vaccination in the context of upcoming shifts in Gavi’s grant model
Emily Kobayashi (Gavi) outlined the transition to the Gavi 6.0 strategy during the 2025 CHIC Symposium. The intervention detailed the consolidation of multiple funding streams into a single holistic grant model and a unified cash envelope to enhance transparency and country sovereignty. Key policy shifts include the introduction of country vaccine budgets with financing ceilings […]
Updates in Cervical Cancer Elimination and HPV Vaccination Landscape: Q&A Session
Emily Kobayashi (Head of HPV Program, Gavi) and regional EPI managers (Guinea, Malawi, Cameroon, DRC) addressed the operationalization of the Gavi 6.0 model at the 2025 CHIC Symposium. The session clarified that the new unified grant integrates Gavi resources with national budgets and partner funding (e.g., World Bank). Key concerns focused on the 4% co-financing […]
Regional HPV Vaccination Investments: Q&A Session
The Q&A addressed future HPV investments under Gavi 6.0, focusing on Health System Strengthening (HSS) funds, prioritization for HPV, and sustainability beyond 2025. Panelists clarified that current HPV‑specific opportunities should be leveraged now, as the next strategy (2026–2030) may shift toward more flexible health system approaches. The Gates Foundation highlighted ongoing work to identify and […]
Gavi Investments
The Gavi session outlined its 2022 “must‑win” priority to scale up HPV vaccination, aiming to immunize 86 million girls by 2025. It detailed support for both Gavi‑eligible and middle‑income countries, including vaccine grants, operational funding, health‑system strengthening, and pooled procurement mechanisms. The presentation highlighted rapid progress post‑COVID, new multi‑age cohort campaigns, and upcoming introductions in […]
DFAT Australia Funding Options
Australia’s National Centre for Immunisation Research presented its role in supporting HPV vaccine scale‑up and cervical cancer elimination across the Indo‑Pacific. Backed by the AUD 620 million “Partnerships for a Healthy Region” program, Australia collaborates with 18 countries on immunisation system strengthening, multi‑age cohorts, and policy support. Two major initiatives were highlighted: the Australian Regional […]